TherapeuticsMD Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited - in thousands, except per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue, net:
License and service revenue	$547	$(53)	$1,094	$800
Operating expenses:
Selling, general and administrative	1,310	1,590	3,865	7,427
Impairment of long-lived assets (Note 4)	—	—	1,261	—
Depreciation & amortization	96	130	409	285
Total operating expenses	1,406	1,720	5,535	7,712
Loss from operations	(859)	(1,773)	(4,441)	(6,912)
Other income (expense):
Interest expense and other financing costs	(3)	(20)	(8)	(115)
Miscellaneous income	295	359	2,023	869
Total other income, net	292	339	2,015	754
Loss from continuing operations before income taxes	(567)	(1,434)	(2,426)	(6,158)
Provision for income taxes	—	—	—	—
Loss from continuing operations, net of income taxes	(567)	(1,434)	(2,426)	(6,158)
Loss from discontinued operations, net of income taxes	(42)	(1,944)	(7)	(3,237)
Net loss	$(609)	$(3,378)	$(2,433)	$(9,395)
Loss per common share, basic and diluted:
Continuing operations	$(0.05)	$(0.13)	$(0.21)	$(0.60)
Discontinued operations, net	—	(0.18)	—	(0.32)
Net loss per common share, basic and diluted	$(0.05)	$(0.32)	$(0.21)	$(0.92)
Weighted average common shares, basic	11,532	10,701	11,532	10,241
Weighted average common shares, diluted	11,532	10,701	11,532	10,241

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.